Eleven Bio's eye drug fails another late-stage study

(Reuters) - Eleven Biotherapeutics Inc said its lead eye drug failed in a late-stage trial in treating patients with severe allergic conjunctivitis, sending its shares down 36 percent in after-market trading.

http://ift.tt/xePdMM

from Reuters: Health News
via animenewspro